Trump unveils deal with Regeneron to lower drug prices as part of most-favored-nation initiative
Summary
President Donald Trump announced a new agreement with drug company Regeneron to lower the prices of its medicines, including a cholesterol drug sold at a reduced price on a special government website. This deal is part of his administration’s broader plan to make drug prices in the U.S. match lower prices seen in other wealthy countries.Key Facts
- President Trump revealed a deal with Regeneron to cut the prices of all its current and future drugs on Medicaid.
- Regeneron agreed to sell the cholesterol drug Praluent for $225 on the government’s discounted drug website, TrumpRx.
- This initiative is part of the “most-favored-nation” strategy to lower U.S. drug prices to the levels paid by other developed nations.
- The deal was announced at the White House and is the last among 17 major pharmaceutical companies contacted by Trump about drug pricing.
- Regeneron committed to investing $27 billion in U.S. research, development, and manufacturing.
- The announcement comes ahead of the November 2026 midterm elections, as the administration highlights efforts to reduce costs on healthcare and other essentials.
- President Trump previously received a Regeneron antibody drug during his 2020 hospitalization for COVID-19.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.